Trial Profile
A Retrospective cohort study comparing efficacy and safety of antitumor necrosis factor biologics (infliximab, adalimumab, or certolizumab pegol) in patients with moderate to severe Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 10 Feb 2017 New trial record